Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celecoxib + lidocaine is a combination of two active pharmaceutical ingredients used for pain management. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor classified as a non-steroidal anti-inflammatory drug (NSAID), which reduces inflammation and pain by inhibiting the synthesis of prostaglandins in inflamed tissues. Lidocaine is a local anesthetic that works by blocking voltage-gated sodium channels, thereby preventing nerve impulse conduction and providing localized numbness or analgesia. This combination may be formulated for topical or other routes to provide both anti-inflammatory and local anesthetic effects, particularly in musculoskeletal or neuropathic pain settings[4][6]. There are no widely approved fixed-dose combination products containing only celecoxib and lidocaine, but such combinations have been studied in clinical trials for acute pain control[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on celecoxib + lidocaine.